NCT02864082 - A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

February 13, 2018

Study Completion Date

December 4, 2018

Conditions

Congenital Ichthyosis

Interventions

DRUG

PAT-001, 0.1%

PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.

DRUG

PAT-001, 0.2%

PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.

DRUG

Vehicle for PAT-001 0.1%

Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.

DRUG

Vehicle for PAT-001 0.2%

Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.

Trial Locations (5)

Paddington Testing Co., Inc, Philadelphia

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

Texas Dermatology and Laser Specialists, San Antonio

TCR Medical Corporation, San Diego

Yale Center for Clinical Investigation, New Haven